HoldingsChannel.com
Audentes Therapeutics insider buying image
The table below summarizes the most recent Audentes Therapeutics insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Audentes Therapeutics insider buys are important for investors to follow.
DateInsiderPriceAmount
4-24-2017
Insider Buy
Partners Iii, Llc 5am
$14.50
CAGR »
$2,499,988.50
172,413 shares
7-25-2016
Insider Buy
Partners Iii, Llc 5am
>10% Owner
$15.00
CAGR »
$1,050,000.00
70,000 shares
7-25-2016
Insider Buy
Advisors Llc Orbimed
Director and >10% Owner
$15.00
CAGR »
$500,010.00
33,334 shares
7-25-2016
Insider Buy
Jonathan Silverstein
Director and >10% Owner
$15.00
CAGR »
$500,010.00
33,334 shares
7-25-2016
Insider Buy
Ventures Iv, Llc Versant
>10% Owner
$15.00
CAGR »
$525,000.00
35,000 shares
7-25-2016
Insider Buy
Thomas Woiwode
Director
$15.00
CAGR »
$525,000.00
35,000 shares
7-25-2016
Insider Buy
James E. Flynn
>10% Owner
$15.00
CAGR »
$6,000,000.00
400,000 shares

Also See: Institutional Holders of BOLD
Also See: SEC filings

BOLD Performance Since Insider Purchase
Below we present the annualized performance delivered by Audentes Therapeutics stock since 4-24-2017 (the date of the most recent insider purchase). The performance of the investment from the time Audentes Therapeutics insider buying occurred is the ultimate test of whether insiders were right about BOLD being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/24/2017
End date: 01/15/2020
Start price/share: $14.43
End price/share: $59.97
Dividends collected/share: $0.00
Total return: 315.59%
Average Annual Total Return: 68.55%
Starting investment: $10,000.00
Ending investment: $41,561.38
Years: 2.73

Audentes Therapeutics Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Audentes Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding BOLD

Quotes delayed 20 minutes

Other companies seeing insider buying close in time to when the Audentes Therapeutics Insider Buying occurred are:

ENI S.p.A. Insider Buying
ONEOK Partners LP Insider Buying
Sunshine Bancorp Insider Buying
Bank of the Ozarks Insider Buying
Hooper Holmes Insider Buying
CONE Midstream Partners LP Insider Buying
Nevada Gold and Casinos Insider Buying
Woodward Insider Buying
Lennox International Insider Buying
Bank of America Insider Buying

Audentes Therapeutics Insider Buying | www.HoldingsChannel.com

Copyright © 2013 - 2020, All Rights Reserved Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.